Company news
Pelthos Therapeutics Inc. (AMEX:PTHS) news
Every Pelthos Therapeutics Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Pelthos Therapeutics Announces First Quarter 2026 Financial Results
May 14, 2026
Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026
May 1, 2026
Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
April 14, 2026
Pelthos Therapeutics Announces CFO Transition
April 10, 2026
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
March 31, 2026
Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results
March 19, 2026
Pelthos Therapeutics to Present at 38th Annual ROTH Conference
March 12, 2026
Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
March 9, 2026
Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 23, 2026
Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics
January 15, 2026
Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance
January 13, 2026
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice
January 5, 2026
Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn
December 23, 2025
Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI Topical Gel, 10.3%
December 5, 2025
Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%
December 4, 2025
Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
December 2, 2025
Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results
November 13, 2025
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
November 7, 2025
Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025
November 5, 2025
Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum
October 9, 2025
Pelthos Therapeutics to Participate in Upcoming September Investor Conferences
September 8, 2025
Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference
September 2, 2025
Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
August 18, 2025
Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum C...
July 10, 2025
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
July 2, 2025